Recent Share Price Recovery Puts Zai Lab Back on Investor Radar
A recent rebound in Zai Lab (NasdaqGM:ZLAB) has drawn attention after a period of sizeable long term value erosion for shareholders. The stock has risen strongly over the past 3 months, prompting fresh questions about valuation.
Over the past five years the share price has fallen about 80.9%, which marks a substantial decline in investor capital. The current recovery phase, together with mixed return figures across different time frames, makes timing and expectations especially important for anyone reviewing the stock now.
Over the past year the total shareholder return is down 16.28%. However, the 90-day share price return of 57.54% and the year-to-date share price return of 51.36% suggest momentum in Zai Lab has recently shifted in a more positive direction.
Compare Zai Lab's sharp rebound with other potential recovery stories by scanning the hand picked 17 high quality undiscovered gems that may still be flying under the radar.
The rebound in Zai Lab could be investors reassessing its drug portfolio and reported revenue growth, or it could just be sentiment snapping back after heavy losses. The next step is to see what the valuation suggests.
Most Popular Narrative: 21.2% Undervalued
The most followed valuation narrative for Zai Lab places fair value at $33.30 compared with the last close at $26.23, which frames the recent rebound in a different light.
Multiple high-potential product launches and label expansions over the next 12-18 months (including VYVGART, bemarituzumab, KarXT, TIVDAK, Tumor Treating Fields), combined with a deep pipeline in oncology and immunology, are expected to significantly increase Zai Lab's addressable market and diversify revenue streams, supporting both top-line growth and future earnings.
Want to see what sits behind that growth story? The narrative leans on sustained revenue expansion, rising margins, and a future earnings multiple that assumes meaningful progress from today.
Result: Fair Value of $33.30 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Zai Lab still faces meaningful risks, including heavy reliance on in licensed assets and intense competition in China that could pressure margins and future revenue potential.
Find out about the key risks to this Zai Lab narrative.
Next Steps
With sentiment on Zai Lab clearly mixed, it makes sense to move fast and check the full picture for yourself, including the 3 key rewards and 1 important warning sign.
Looking For More Investment Ideas Beyond Zai Lab?
If Zai Lab has your attention, do not stop there. Your next strong idea might be just a few filters away in the Simply Wall Street Screener.
- Spot potential bargains early by checking companies that appear mispriced on key fundamentals through the 47 high quality undervalued stocks.
- Prioritise resilience by reviewing businesses with strong finances using the list of solid balance sheet and fundamentals (53 results).
- Focus on getting paid while you wait by scanning income opportunities via the 11 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com